60
Participants
Start Date
February 6, 2025
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2026
CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
CK-4021586 administered orally
Placebo to match CK-4021586
Placebo administered orally
RECRUITING
NYU Langone Health, New York
RECRUITING
DelRicht Research, Vienna
RECRUITING
New Generation of Medical Research, Hialeah
RECRUITING
Cleveland Clinic Florida, Weston
RECRUITING
Eastern Shore Research Institute, LLC, Fairhope
RECRUITING
The Lindner Center for Research & Education at The Christ Hospital, Cincinnati
RECRUITING
Froedtert Hospital - Center for Advanced Care, Milwaukee
RECRUITING
Mayo Clinic, Rochester
RECRUITING
Methodist Medical Center of Illinois, Peoria
RECRUITING
Washington University Center for Advanced Medicine, St Louis
RECRUITING
Louisiana Heart Center, Slidell
RECRUITING
University of Texas Southwestern Medical Center, Dallas, Dallas
RECRUITING
Profound Research LLC, Pasadena
RECRUITING
Blue Coast Research Center, LLC, Vista
RECRUITING
FOMAT - Comprehensive Cardiovascular Care, Santa Maria
RECRUITING
University of California, San Francisco - Heart and Vascular Center, San Francisco
RECRUITING
Oregon Health and Science University, Portland
RECRUITING
Swedish Heart & Vascular Institute, Advanced Cardiac Support Program, Seattle
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Morristown Medical Center, Morristown
Lead Sponsor
Cytokinetics
INDUSTRY